We are live on ! Find out more
SXTC icon

China SXT Pharmaceuticals
SXTC

1 hedge funds and large institutions have $3.19K invested in China SXT Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.01% less ownership

Funds ownership: 0.01% → 0% (-0.01%)

67% less funds holding

Funds holding: 3 → 1 (-2)

98% less capital invested

Capital invested by funds: $199K → $3.19K (-$196K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
1
Holders Change
-2
Holders Change %
-66.67%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
MG
Marex Group
-$164K
2
UBS Group
UBS Group
Switzerland
-$11.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
Acadian Asset Management
1
Acadian Asset Management
Massachusetts
$3K – – –
Qube Research & Technologies (QRT)
2
Qube Research & Technologies (QRT)
United Kingdom
$173 – – –
UBS Group
3
UBS Group
Switzerland
$13 -$11.8K -5 Closed
MG
4
Marex Group
– -$164K -34 Closed

SXTC Hedge Fund Activity: Q1 2024 in Review

1 of the 6,945 institutional investors tracked by Wall St. Rank reported a position in China SXT Pharmaceuticals (SXTC) for Q1 2024, worth a combined $3.19K — down 98% from $199K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of SXTC and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Marex Group, exiting entirely with an estimated $164K sold.

  • 1 institutional investor held China SXT Pharmaceuticals (SXTC) as of Q1 2024, down from 3 in Q4 2023.
  • Funds reported $3.19K of China SXT Pharmaceuticals stock for Q1 2024, down 98% quarter-over-quarter.
  • 0 funds opened new China SXT Pharmaceuticals positions in Q1 2024 and 2 closed out, a net change of -2 holders.
  • The largest China SXT Pharmaceuticals seller in Q1 2024 was Marex Group, an estimated $164K sold.

Based on aggregated 13F filings for Q1 2024.